Spatially addressed combinatorial protein libraries for recombinant antibody discovery and optimization

Nature Biotechnology

Volumn 28, Issue 11, 2010, Pages 1195-1202

  Mao, Hongyuan ^a   Graziano, James J ^a   Chase, Tyson M A ^a   Bentley, Cornelia A ^a   Bazirgan, Omar A ^a   Reddy, Neil P ^a   Song, Byeong Doo ^a,c   Smider, Vaughn V ^a,b  

^a Fabrus LLC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Scripps Korea Antibody Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AFFINITIES; COMPOUND LIBRARIES; DNA SYNTHESISS; GERMLINE; IN-CELL; NANOMOLAR RANGE; PROTEIN DRUGS; PROTEIN EXPRESSIONS; PROTEIN LIBRARY; RECOMBINANT ANTIBODY; SCREENING ASSAYS; SMALL MOLECULES;

BINDING ENERGY; LIBRARIES; OPTIMIZATION;

ANTIBODIES;

ANTIGEN; DELTA LIKE LIGAND 4 ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; COMBINATORIAL LIBRARY; DNA SYNTHESIS; HUMAN; HUMAN CELL; METHODOLOGY; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SCREENING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; BINDING SITES; CHEMILUMINESCENT MEASUREMENTS; CHO CELLS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRICETINAE; CRICETULUS; EPITOPE MAPPING; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149322603     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1694     Document Type: Article

References (69)

1. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefned specifcity. Nature 256, 495-497 (1975).
2. Jin, A. et al. A rapid and effcient single-cell manipulation method for screening antigen-specifc antibody-secreting cells from human peripheral blood. Nat. Med. 15, 1088-1092 (2009).
3. Love, J.C., Ronan, J.L., Grotenbreg, G.M., van der Veen, A.G. & Ploegh, H.L. A microengraving method for rapid selection of single cells producing antigen-specifc antibodies. Nat. Biotechnol. 24, 703-707 (2006).
4. Hoogenboom, H.R. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23, 1105-1116 (2005).
5. Huse, W.D. et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246, 1275-1281 (1989).
6. McCafferty, J., Griffths, A.D., Winter, G. & Chiswell, D.J. Phage antibodies: flamentous phage displaying antibody variable domains. Nature 348, 552-554 (1990).
7. Hanes, J., Jermutus, L., Weber-Bornhauser, S., Bosshard, H.R. & Pluckthun, A. Ribosome display effciently selects and evolves high-affnity antibodies in vitro from immune libraries. Proc. Natl. Acad. Sci. USA 95, 14130-14135 (1998).
8. Boder, E.T. & Wittrup, K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553-557 (1997).
9. Beerli, R.R. et al. Isolation of human monoclonal antibodies by mammalian cell display. Proc. Natl. Acad. Sci. USA 105, 14336-14341 (2008).
10. Ho, M., Nagata, S. & Pastan, I. Isolation of anti-CD22 Fv with high affnity by Fv display on human cells. Proc. Natl. Acad. Sci. USA 103, 9637-9642 (2006).
11. Levitan, B. Stochastic modeling and optimization of phage display. J. Mol. Biol. 277, 893-916 (1998).
12. Wang, L., Martin, B., Brenneman, R., Luttrell, L.M. & Maudsley, S. Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders. J. Pharmacol. Exp. Ther. 331, 340-348 (2009).
13. Fodor, S.P. et al. Light-directed, spatially addressable parallel chemical synthesis. Science 251, 767-773 (1991).
14. Ziauddin, J. & Sabatini, D.M. Microarrays of cells expressing defned cDNAs. Nature 411, 107-110 (2001).
15. Diller, D.J. The synergy between combinatorial chemistry and high-throughput screening. Curr. Opin. Drug Discov. Devel. 11, 346-355 (2008).
16. Polinsky, A. Combichem and chemoinformatics. Curr. Opin. Drug Discov. Devel. 2, 197-203 (1999).
17. Kauffman, S.A. The Origins of Order (Oxford University Press; 1993).
18. Bachmann, M.F., Kundig, T.M., Kalberer, C.P., Hengartner, H. & Zinkernagel, R.M. How many specifc B cells are needed to protect against a virus? J. Immunol. 152, 4235-4241 (1994).
19. Cohn, M. & Langman, R.E. The protection: the unit of humoral immunity selected by evolution. Immunol. Rev. 115, 11-147 (1990).
20. Xu, J.L. & Davis, M.M. Diversity in the CDR3 region of V(H) is suffcient for most antibody specifcities. Immunity 13, 37-45 (2000).
21. Babor, M. & Kortemme, T. Multi-constraint computational design suggests that native sequences of germline antibody H3 loops are nearly optimal for conformational fexibility. Proteins 75, 846-858 (2009).
22. Patten, P.A. et al. The immunological evolution of catalysis. Science 271, 1086-1091 (1996).
23. Sethi, D.K., Agarwal, A., Manivel, V., Rao, K.V. & Salunke, D.M. Differential epitope positioning within the germline antibody paratope enhances promiscuity in the primary immune response. Immunity 24, 429-438 (2006).
24. Thielges, M.C., Zimmermann, J., Yu, W., Oda, M. & Romesberg, F.E. Exploring the energy landscape of antibody-antigen complexes: protein dynamics, fexibility, and molecular recognition. Biochemistry 47, 7237-7247 (2008).
25. Yin, J., Beuscher, A.E.t., Andryski, S.E., Stevens, R.C. & Schultz, P.G. Structural plasticity and the evolution of antibody affnity and specifcity. J. Mol. Biol. 330, 651-656 (2003).
26. Zimmermann, J. et al. Antibody evolution constrains conformational heterogeneity by tailoring protein dynamics. Proc. Natl. Acad. Sci. USA 103, 13722-13727 (2006).
27. Nguyen, H.P. et al. Germline antibody recognition of distinct carbohydrate epitopes. Nat. Struct. Biol. 10, 1019-1025 (2003).
28. Thomson, C.A. et al. Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO J. 27, 2592-2602 (2008).
29. Matsuda, F. et al. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J. Exp. Med. 188, 2151-2162 (1998).
30. Smider, V. & Chu, G. The end-joining reaction in V(D)J recombination. Semin. Immunol. 9, 189-197 (1997).
31. Gilfllan, S., Benoist, C. & Mathis, D. Mice lacking terminal deoxynucleotidyl transferase: adult mice with a fetal antigen receptor repertoire. Immunol. Rev. 148, 201-219 (1995). (Pubitemid 26010548)
32. Holt, L.J., Bussow, K., Walter, G. & Tomlinson, I.M. By-passing selection: direct screening for antibody-antigen interactions using protein arrays. Nucleic Acids Res. 28, E72 (2000).
33. Corbett, S.J., Tomlinson, I.M., Sonnhammer, E.L., Buck, D. & Winter, G. Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination. J. Mol. Biol. 270, 587-597 (1997).
34. Brezinschek, H.P. et al. Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. J. Clin. Invest. 99, 2488-2501 (1997).
35. Kim, D. et al. Directed evolution and identifcation of control regions of ColE1 plasmid replication origins using only nucleotide deletions. J. Mol. Biol. 351, 763-775 (2005).
36. Leonard, B., Sharma, V. & Smider, V. Co-expression of antibody fab heavy and light chain genes from separate evolved compatible replicons in E. coli. J. Immunol. Methods 317, 56-63 (2006).
37. Wollerton, M.C., Wales, R., Bullock, J.A., Hudson, I.R. & Beggs, M. Automation and optimization of protein expression and purifcation on a novel robotic platform. JALA 11, 291-303 (2006).
38. Smider, V. et al. Combinatorial antibody libraries and uses thereof. PCT/ US2009/063299 (2009).
39. Shutter, J.R. et al. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev. 14, 1313-1318 (2000).
40. Yoneya, T. et al. Molecular cloning of delta-4, a new mouse and human Notch ligand. J. Biochem. 129, 27-34 (2001).
41. Li, J.L. et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 67, 11244-11253 (2007).
42. Mailhos, C. et al. Delta4, an endothelial specifc notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69, 135-144 (2001).
43. Patel, N.S. et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin. Cancer Res. 12, 4836-4844 (2006).
44. Hoey, T. et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168-177 (2009).
45. Patel, N.S. et al. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 65, 8690-8697 (2005).
46. Segarra, M. et al. Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood 112, 1904-1911 (2008).
47. Yan, M. et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 463, E6-E7 (2010).
48. Nefedova, Y., Cheng, P. , Alsina, M., Dalton, W.S. & Gabrilovich, D.I. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 103, 3503-3510 (2004).
49. Purow, B.W. et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 65, 2353-2363 (2005).
50. de Kruif, J., Boel, E. & Logtenberg, T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol. 248, 97-105 (1995).
51. Mao, S. et al. Phage-display library selection of high-affnity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. Proc. Natl. Acad. Sci. USA 96, 6953-6958 (1999).
52. Marks, J.D. et al. By-passing immunization: building high affnity human antibodies by chain shuffing. Bio/Technology 10, 779-783 (1992).
53. Griffths, A.D. et al. Isolation of high affnity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245-3260 (1994).
54. Sheets, M.D. et al. Effcient construction of a large nonimmune phage antibody library: the production of high-affnity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. USA 95, 6157-6162 (1998).
55. Vaughan, T.J. et al. Human antibodies with sub-nanomolar affnities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14, 309-314 (1996).
56. Chandonia, J.M. & Brenner, S.E. The impact of structural genomics: expectations and outcomes. Science 311, 347-351 (2006).
57. Joachimiak, A. High-throughput crystallography for structural genomics. Curr. Opin. Struct. Biol. 19, 573-584 (2009).
58. Brooks, C.L. et al. Exploration of specifcity in germline monoclonal antibody recognition of a range of natural and synthetic epitopes. J. Mol. Biol. 377, 450-468 (2008).
59. Barbas, C.F. III et al. In vitro evolution of a neutralizing human antibody to human immunodefciency virus type 1 to enhance affnity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. USA 91, 3809-3813 (1994).
60. Cumbers, S.J. et al. Generation and iterative affnity maturation of antibodies in vitro using hypermutating B-cell lines. Nat. Biotechnol. 20, 1129-1134 (2002).
61. Hawkins, R.E., Russell, S.J. & Winter, G. Selection of phage antibodies by binding affnity. Mimicking affnity maturation. J. Mol. Biol. 226, 889-896 (1992).
62. Jackson, J.R., Sathe, G., Rosenberg, M. & Sweet, R. In vitro antibody maturation. Improvement of a high affnity, neutralizing antibody against IL-1 beta. J. Immunol. 154, 3310-3319 (1995).
63. Wu, H. et al. Stepwise in vitro affnity maturation of Vitaxin, an alphav beta3-specifc humanized mAb. Proc. Natl. Acad. Sci. USA 95, 6037-6042 (1998).
64. McCall, A.M. et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecifc scFv that triggers CD16-dependent tumor cytolysis. Mol. Immunol. 36, 433-446 (1999).
65. Binz, H.K., Amstutz, P. & Pluckthun, A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23, 1257-1268 (2005).
66. Skerra, A. Alternative non-antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 18, 295-304 (2007).
67. Miller, D.J. & Rodriguez, M. A monoclonal autoantibody that promotes central nervous system remyelination in a model of multiple sclerosis is a natural autoantibody encoded by germline immunoglobulin genes. J. Immunol. 154, 2460-2469 (1995).
68. Liu, Z. et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood 110, 2408-2413 (2007).
69. Wang, J. et al. Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis. Cell. Mol. Immunol. 5, 55-60 (2008).